Search Results - "Nielsen, D.L."

434 Phase II Study of Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/− Trastuzumab Followed by Docetaxel in Locally Advanced Breast Cancer (LABC) by Tuxen, M.K, Cold, S, Tange, U.B, Soendergaard, S.B, Nielsen, D.L

Get full text

Model development of a Bayesian Belief Network for managing inundation events for wetland fish by Vilizzi, L., Price, A., Beesley, L., Gawne, B., King, A.J., Koehn, J.D., Meredith, S.N., Nielsen, D.L.

“…Wetlands are essential components of floodplain–river ecosystems that often suffer degradation due to river regulation. To this end, the application of…”
Get full text

Intrahepatic and systemic therapy with oxaliplatin combined with capecitabine in patients with hepatic metastases from breast cancer by Nielsen, D.L, Nørgaard, H, Vestermark, L.W, Pfeiffer, P, Jensen, B.K, Nelausen, K.M, Bergenfeldt, M, Hermann, K.L, Jensen, B.V

“…Abstract Background The aim was to evaluate activity and toxicity of hepatic arterial infusion of oxaliplatin in combination with capecitabine in patients with…”
Get full text

The belief index: An empirical measure for evaluating outcomes in Bayesian belief network modelling by Vilizzi, L., Price, A., Beesley, L., Gawne, B., King, A.J., Koehn, J.D., Meredith, S.N., Nielsen, D.L., Sharpe, C.P.

“…► Bayesian networks (BNs) are a widespread tool in ecological modelling. ► Parameterisation of BNs is often achieved with multiple experts. ► BNs are commonly…”
Get full text

460 Gemcitabine, carboplatin and paclitaxel as neoadjuvant combination chemotherapy in patients with locally advanced (stage III) or inflammatory breast cancer – a non-anthracycline alternative by Kambye, C, Nielsen, D.L, Balslev, E

Get full text

56P Serum protein signatures as potential novel diagnostic biomarkers for biliary tract cancer by Christensen, T.D., Maag, E., Larsen, O., Feltoft, C.L., Leerhøy, B., Chen, I.M., Hansen, C.P., Nielsen, D.L., Johansen, J.S.

Get full text

Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer by Schou, J.V., Larsen, F.O., Sørensen, B.S., Abrantes, R., Boysen, A.K., Johansen, J.S., Jensen, B.V., Nielsen, D.L., Spindler, K.L.

“…Treatment of patients with locally advanced rectal cancer (LARC) is based on a combination of chemo-radiotherapy (CRT) and surgery. The rate of distant…”
Get full text

624P - High circulating miR-1247 is a marker for poor prognosis in patients with metastatic colorectal cancer treated with chemotherapy and cetuximab by Schou, J.V., Sztupinszki, Z., Johansen, J.S., Nielsen, D.L., Glimelius, B., Qvortrup, C., Sorbye, H., Jensen, B Vittrup, Pfeiffer, P.

“…MicroRNAs (miRs) are small non-coding RNAs. Circulating miRs in plasma are deregulated in patients with metastatic colorectal cancer (mCRC). The aim was to…”
Get full text

High circulating miR-1247 is a marker for poor prognosis in patients with metastatic colorectal cancer treated with chemotherapy and cetuximab by Schou, J.V., Sztupinszki, Z., Johansen, J.S., Nielsen, D.L., Glimelius, B., Qvortrup, C., Sorbye, H., Jensen, B Vittrup, Pfeiffer, P.

Get full text

Age-related Differences in Recall of Information and Handling of Chemotherapy-related Side Effects in Cancer Patients: The ReCap Study by Lund, Cecilia Margareta, Mikkelsen, M K, Theile, S, Michelsen, H M, Schultz, M, Sengeløv, L, Nielsen, D L

“…To prevent severe toxicity and hospital admissions, adequate management and recall of information about side effects are crucial and health literacy plays an…”
Get full text

1539P Signature protein biomarkers in serum for diagnosis of pancreatic ductal adenocarcinoma by Lindgaard, S.C., Maag, E., Chen, I., Johansen, A.Z., Hansen, C.P., Hasselby, J.P., Jensen, B.V., Bojesen, S.E., Nielsen, K.R., Nielsen, D.L., Johansen, J.S.

Get full text

29P Circulating proteins associated with immunotherapy efficacy in patients with pancreatic ductal adenocarcinoma by Christensen, T.D., Maag, E., Theile, S., Madsen, K., Lindgaard, S.C., Nielsen, D.L., Chen, I., Johansen, J.S.

Get full text

Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer by Schou, J.V., Larsen, F.O., Rasch, L., Linnemann, D., Langhoff, J., Høgdall, E., Nielsen, D.L., Vistisen, K., Fromm, A., Jensen, B.V.

“…Preoperative chemoradiation in patients with locally advanced rectal cancer has no impact on overall survival (OS) and distant recurrences. The aim of the…”
Get full text

An open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics of oral administration of irinotecan in adult patients with solid tumors by Palshof, J A, Kümler, I, Sørensen, P G, Jensen, B V, Nielsen, D L

Get full text

Internal Survey of Source Data in Clinical Trials by Nelausen, K.M., Michelsen, H.M., Jensen, B.K., Sengeloev, L., Olsen, M., Nielsen, D.L.

Get full text

1407PINTERNAL SURVEY OF SOURCE DATA IN CLINICAL TRIALS by Nelausen, K.M., Michelsen, H.M., Jensen, B.K., Sengeloev, L., Olsen, M., Nielsen, D.L.

“…Abstract Aim: Ensuring correct and complete source data in clinical trials is of outmost importance. Journal audits in the Dept. of Oncology revealed that…”
Get full text

Hepatic arterial infusion (HAI) of oxaliplatin with capecitabine in first line treatment of patients (pts) with liver limited metastases from colorectal cancer (LLmCRC) by Vittrup, B V, Nørgaard, H H, Bergenfeldt, M, Larsen, F O, Høgdall, E, Johansen, J S, Sidenius Johansen, J S, Hermann, H K, Nielsen, D L

Get full text

Cell free DNA and hepatic arterial infusion of oxaliplatin plus systemic capecitabine for patients with colorectal cancer liver metastases by Boysen, A K, Schou, J V, Jensen, B V, Nielsen, D L, Sørensen, B S, Johansen, J S, Spindler, K-L G

Get full text

Circulating immune-related proteins associated with immune checkpoint inhibitor efficacy in patients with pancreatic ductal adenocarcinoma by Christensen, T.D., Maag, E., Theile, S., Madsen, K., Lindgaard, S.C., Hasselby, J.P., Nielsen, D.L., Johansen, J.S., Chen, I.M.

“…Most patients with pancreatic ductal adenocarcinoma (PDAC) do not benefit from immune checkpoint inhibitor treatment. However, the phase II study CheckPAC…”
Get full text

Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials by Mau-Sorensen, M., van Bussel, M., Kuipers, M., Nielsen, D.L., Verheul, H.M., Aftimos, P., de Jonge, M.J.A., van Triest, B., Falkenius, J., Debus, J., Troost, E., Samuels, M., Sarholz, B., Budach, V., Goel, S., Locatelli, G., Geertsen, P.F.

Get full text